Checkpoint inhibitor–induced rheumatic complications often arise lateMarch 15, 2021Rheumatoid ArthritisLupus & Connective Tissue DiseasesSpondyloarthropathiesAnkylosing spondylitisPsoriatic Arthritis
Novel lupus therapies take center stageMarch 9, 2021Lupus & Connective Tissue DiseasesOsteoarthritisRheumatoid Arthritis
ACR, AAD, AAO, RDS issue joint statement on safe use of hydroxychloroquineMarch 2, 2021Lupus & Connective Tissue DiseasesRheumatoid ArthritisPediatrics
Methotrexate-associated hepatotoxicity risk differs between psoriasis, PsA, and RA patientsFebruary 25, 2021Psoriatic ArthritisRheumatoid Arthritis
COVID-19 vaccination recommended for rheumatology patientsFebruary 24, 2021COVID-19 UpdatesAnkylosing spondylitisGoutLupus & Connective Tissue DiseasesOsteoarthritisOsteoporosisPediatrics
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseasesFebruary 16, 2021Rheumatoid ArthritisLupus & Connective Tissue Diseases
Rheumatologic disease activity an important influencer of COVID-19 death riskFebruary 5, 2021COVID-19 UpdatesRheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisLupus & Connective Tissue DiseasesGoutAnkylosing spondylitis
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)February 5, 2021Rheumatoid ArthritisPsoriatic ArthritisPediatrics
Patients with early arthritis may need tailored treatmentsFebruary 2, 2021Rheumatoid ArthritisPsoriatic Arthritis
Tofacitinib for RA misses the mark in safety studyFebruary 1, 2021Rheumatoid ArthritisPsoriatic ArthritisPediatrics
Arthritis drugs ‘impressive’ for severe COVID but not ‘magic cure’January 15, 2021COVID-19 UpdatesRheumatoid Arthritis
EULAR recommendations define strategies to improve adherence in RMDsJanuary 4, 2021Lupus & Connective Tissue DiseasesRheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisPediatricsOsteoporosisOsteoarthritis
